Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
320 participants
INTERVENTIONAL
2019-12-31
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The pathophysiological hypothesis of this research is that there is a change in the fetal fraction (FF) of fetal circulating free DNA in patients with autoimmune disease (AID). The underlying mechanism would be a massive release of maternal cfDNA responsible for a dilution of fetal cfDNA. This dilution of fetal cfDNA would result in a decrease in the estimate of the foetal fraction of circulating free DNA. However, when the foetal fraction of circulating free DNA is insufficient (4% most often), screening for Trisomy 21 (T21) by fetal circulating free DNA becomes uninterpretable (NC for "non-contributory" result), and cannot be used to assess the risk of T21. In this case, the dose of fetal circulating free DNA can be performed again after 15 days, as the amount of fetal circulating free DNA increases with gestation. In a small number of cases the result will remain NC.
As tests using DNA are becoming more widespread, it is important to prospectively evaluate the results of these tests in the population of patients with AID, which represents about 3 to 5% of pregnant women.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trisomy of Chromosome 21 Diagnosis by High Output Sequencing
NCT01118507
First Trimester Risk Assessment Based on Ultrasound and Cell-free DNA vs Combined Screening
NCT04077060
Technical Feasibility of the cfDNA Test for Non-invasive Cytogenetic Analysis of Early Miscarriages Versus the Gold Standard Microarray
NCT05900076
Free DNA and Nucleosome Concentrations in Pathological Pregnancies
NCT01736826
Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood
NCT01852708
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objective of this study is to compare the rate of NC in a population of patients with DIA to that of a population of patients without MAI when screened for T21 by the cfDNA study in the first trimester of pregnancy.
The secondary objectives are :
* To assess the performance of fetal cfDNA for T21 screening in the population of PATIENTS with AID and to compare them with performance in the non-auto immune disease population.
* To assess the performance of the combined first trimester screening for T21 screening and compare it with those of fetal cfDNA in the population of patients with AID.
* In patients with an NC result, analysis of the distribution of fetal fractions according to the presence and severity of maternal autoimmune pathologies. The distribution will be compared to that of the control population.
* To assess the association between fetal fraction and the occurrence of vascular complications of pregnancy in both groups with and without auto immune disease.
AFFEPI is a prospective multicenter, interventional, exposed/non-exposed cohort study
There are two group :
Exposed group: Any patient with a auto immune disease followed at one of the 14 centres who wants to be screened for T21.
Unexposed group: Patients who do not carry an auto immune disease identified at the interview (no history of auto immune disease; no symptoms suggestive of a auto immune disease).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exposed group (patient with an autoimmunise disease)
Any patient with an autoimmune disease followed at one of the 14 centres who wants to be screened for T21.
the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Non Exposed group (patient without an autoimmunise disease)
the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Single-fetal pregnancy with a term between 11 and 13-6 weeks of amenorrhea (SA) from spontaneous pregnancy or by medical assistance to procreation.
* Age ≥ 18 years
* Affiliated with a social security or beneficiary scheme
* Desire for natal screening of T21, not yet realized
* Patient with a condition on the following list: \[see Chapter 7.2\]
Patients in the unexposed group:
* Single-fetal pregnancy with a term between 11 and 13-6 weeks of amenorrhea (SA) from spontaneous pregnancy or by medical assistance to procreation.
* Age ≥ 18 years
* Affiliated with a social security or beneficiary scheme
* Desire for natal screening of T21, not yet realized
* No pathology that meets the list mentioned in the above section
* Clinically asymptomatic patient with no clinical symptoms suggestive of AID: arthralgias, skin or mucous disease, dry syndrome, Raynaud syndrome, purpura.
* Patient respecting frequency pairing
Exclusion Criteria
* Multiple pregnancy
* No first trimester ultrasound (between 11 and 13-6 SA)
* Screening for unwanted T21
* Patients already included in an interventional research protocol
* Morphological abnormalities on first trimester ultrasound and/or nucal clarity - 3.5mm
* Patient under the protection of justice
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CERBA laboratory
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Antoine Béclère
Clamart, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A01827-50
Identifier Type: OTHER
Identifier Source: secondary_id
APHP180669
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.